Zacks " Onyx All Set For Growth" Article: Catalyst Filled 2013 for Onyx. LINK.
Article : Catalyst-Filled 2013 for Onyx
ZacksBy Zacks Equity Research / Updated January 23, 2013
Onyx Pharma, which was a one-product company until a year back, has successfully transformed into a multi-product company. With two recent product approvals (Kyprolis and Stivarga) in its bag and Nexavar continuing to perform well, Onyx Pharma looks all set for growth. We expect 2013 to be a catalyst-filled year for Onyx Pharma as the company works on expanding the labels of currently marketed products and progresses with the development of other candidates.